145 related articles for article (PubMed ID: 33769084)
1. The importance of quality critical reagents for the entire developmental lifecycle of a biopharmaceutical: a pharmacokinetic case study.
Mayer AP; Fraley KJ
Bioanalysis; 2021 May; 13(10):817-827. PubMed ID: 33769084
[No Abstract] [Full Text] [Related]
2. Adventures in critical reagent lot changes in ligand-binding assays: redevelopment, bridging and additional processing requirements.
Rauwerdink A; Benson M; Jayne A; Babu S; St Charles J; Smith A
Bioanalysis; 2021 May; 13(10):771-777. PubMed ID: 33884890
[No Abstract] [Full Text] [Related]
3. Critical reagents for ligand-binding assays: process development methodologies to enable high-quality reagents.
Kittinger C; Delmar J; Hewitt L; Holcomb R; Jones C; Jones H; Kubiak R; Lee N; McClenny LC; Mody N; O'Connor E
Bioanalysis; 2022 Feb; 14(3):117-135. PubMed ID: 35019733
[TBL] [Abstract][Full Text] [Related]
4. Characterization of critical reagents in ligand-binding assays: enabling robust bioanalytical methods and lifecycle management.
Geist BJ; Egan AC; Yang TY; Dong Y; Shankar G
Bioanalysis; 2013 Jan; 5(2):227-44. PubMed ID: 23330563
[TBL] [Abstract][Full Text] [Related]
5. The impact of ligand binding based assays critical reagent characterization and storage.
Haulenbeek J; Beaver CJ
Bioanalysis; 2021 May; 13(10):797-805. PubMed ID: 34002637
[TBL] [Abstract][Full Text] [Related]
6. Critical ligand binding reagent preparation/selection: when specificity depends on reagents.
Rup B; O'Hara D
AAPS J; 2007 May; 9(2):E148-55. PubMed ID: 17614357
[TBL] [Abstract][Full Text] [Related]
7. Critical reagent generation, characterization, handling and storage workflows: impact on ligand binding assays.
Oquendo E; Savoie J; Swenson JM; Grimaldi C
Bioanalysis; 2021 May; 13(10):847-860. PubMed ID: 33890503
[TBL] [Abstract][Full Text] [Related]
8. Ligand binding assays in the 21st century laboratory: recommendations for characterization and supply of critical reagents.
O'Hara DM; Theobald V; Egan AC; Usansky J; Krishna M; TerWee J; Maia M; Spriggs FP; Kenney J; Safavi A; Keefe J
AAPS J; 2012 Jun; 14(2):316-28. PubMed ID: 22415613
[TBL] [Abstract][Full Text] [Related]
9. Risk-based Strategy to Determine Testing Requirement for the Removal of Residual Process Reagents as Process-related Impurities in Bioprocesses.
Qiu J; Li K; Miller K; Raghani A
PDA J Pharm Sci Technol; 2015; 69(3):334-45. PubMed ID: 26048741
[TBL] [Abstract][Full Text] [Related]
10. Addressing matrix effects in ligand-binding assays through the use of new reagents and technology.
Chilewski SD; Mora JR; Gleason C; DeSilva B
Bioanalysis; 2014 Apr; 6(8):1059-67. PubMed ID: 24830890
[TBL] [Abstract][Full Text] [Related]
11. Biotransformation and in vivo stability of protein biotherapeutics: impact on candidate selection and pharmacokinetic profiling.
Hall MP
Drug Metab Dispos; 2014 Nov; 42(11):1873-80. PubMed ID: 24947971
[TBL] [Abstract][Full Text] [Related]
12. Recombinant Anti-idiotypic Antibodies in Ligand Binding Assays for Antibody Drug Development.
Harth S; Frisch C
Methods Mol Biol; 2021; 2261():291-306. PubMed ID: 33420997
[TBL] [Abstract][Full Text] [Related]
13. Quality requirements for critical assay reagents used in bioanalysis of therapeutic proteins: what bioanalysts should know about their reagents.
Staack RF; Stracke JO; Stubenrauch K; Vogel R; Schleypen J; Papadimitriou A
Bioanalysis; 2011 Mar; 3(5):523-34. PubMed ID: 21388265
[TBL] [Abstract][Full Text] [Related]
14. Bioanalytical considerations in the comparability assessment of biotherapeutics.
Lee JW; Wang YM; Moxness M; DeSilva B
Bioanalysis; 2011 Mar; 3(6):613-22. PubMed ID: 21417731
[TBL] [Abstract][Full Text] [Related]
15. Ligand binding assay critical reagents and their stability: recommendations and best practices from the Global Bioanalysis Consortium Harmonization Team.
King LE; Farley E; Imazato M; Keefe J; Khan M; Ma M; Pihl KS; Sriraman P
AAPS J; 2014 May; 16(3):504-15. PubMed ID: 24687208
[TBL] [Abstract][Full Text] [Related]
16. Lot-to-lot reproducibility, stability and life cycle management of antibody reagents for flow cytometry.
Lanham DF
Bioanalysis; 2021 May; 13(10):745-759. PubMed ID: 34009005
[TBL] [Abstract][Full Text] [Related]
17. Universal immunoassay applied during early development of large molecules to understand impact of immunogenicity on biotherapeutic exposure.
Bautista AC; Salimi-Moosavi H; Jawa V
AAPS J; 2012 Dec; 14(4):843-9. PubMed ID: 22941399
[TBL] [Abstract][Full Text] [Related]
18. Critical reagent screening and characterization: benefits and approaches for protein biomarker assays by hybrid LC-MS.
Santockyte R; Zeng J; Zheng N
Bioanalysis; 2019 Apr; 11(8):785-795. PubMed ID: 30994008
[TBL] [Abstract][Full Text] [Related]
19. Critical reagent inventory management system and web portal specifically optimized for supporting external clients.
Feauto JA; Davis A; Delhaye RC; Abdeen SJ; Gill HN; Colwell JE; Chiappetta M; Clor EE; Bowsher RR
Bioanalysis; 2022 Jun; 14(12):869-879. PubMed ID: 35904158
[TBL] [Abstract][Full Text] [Related]
20. Increasing robustness, reliability and storage stability of critical reagents by freeze-drying.
Emrich T; Stracke JO; Guo X; Damhjell K; Moelleken J; Vogel R; Stubenrauch KG; Staack RF
Bioanalysis; 2021 May; 13(10):829-840. PubMed ID: 33890493
[No Abstract] [Full Text] [Related]
[Next] [New Search]
